EMA Refused: Masican (masitinib) — AB Science

View source ↗

Summary

EMA refused Masican (masitinib) for gastrointestinal stromal tumors; the marketing authorization application was rejected.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Masican (masitinib)

Snippet

Status: Refused. Therapeutic area: Gastrointestinal Stromal Tumors. MAH: AB Science. Decision date: 22/11/2013. Orphan medicine